# Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma

> **NCT03099265** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** neoadjuvant mFOLFIRINOX
- **DRUG:** Stereotactic body radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT03099265
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-26
- **Primary completion:** 2019-09-18
- **Final completion:** 2019-09-18
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Paused due to COVID. A determination was made to stop the study because it would be impossible to reach the 65% resection rate as outlined in the protocol.
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099265, "Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03099265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*